US20180255781A1 - Antimicrobial Composition - Google Patents

Antimicrobial Composition Download PDF

Info

Publication number
US20180255781A1
US20180255781A1 US15/975,482 US201815975482A US2018255781A1 US 20180255781 A1 US20180255781 A1 US 20180255781A1 US 201815975482 A US201815975482 A US 201815975482A US 2018255781 A1 US2018255781 A1 US 2018255781A1
Authority
US
United States
Prior art keywords
amount
antimicrobial
antimicrobial composition
composition according
benzalkonium chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/975,482
Inventor
Jay Reubens
David Dyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Safehands Solutions LLC
Original Assignee
Safehands Solutions LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Safehands Solutions LLC filed Critical Safehands Solutions LLC
Priority to US15/975,482 priority Critical patent/US20180255781A1/en
Publication of US20180255781A1 publication Critical patent/US20180255781A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/10Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds
    • A01N57/12Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing acyclic or cycloaliphatic radicals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02Amines; Quaternary ammonium compounds
    • A01N33/12Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • A61K8/416Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations

Definitions

  • the invention relates to antimicrobial compositions, and more particularly, to antimicrobial compositions that use quaternary ammonium based active ingredients, such as benzalkonium chloride in combination with phospholipids and glycols.
  • alcohol-free and alcohol-containing The wide variety of instant hand sanitizers available to consumers may be grouped into two categories: alcohol-free and alcohol-containing. Of the former category, quaternary ammonium compounds are most frequently employed as the antimicrobial active ingredient. Of the latter category, ethanol at a concentration range of 62-70% w/w is most readily available on the market. In general, both alcohol-free and alcohol-containing products are effective at reducing germs on the skin with a single use. With repeated use, however, alcohol-free products show a significant persistence of antimicrobial activity while alcohol-containing products appear to increase the skin's ability to carry disease-causing pathogens.
  • chlorhexidine An antimicrobial active ingredient that has been used to sanitize hands is chlorhexidine (CHX).
  • chlorhexidine gluconate (CHX-gluconate), a particular salt of chlorhexidine and gluconate, is widely used as a surgical hand scrub and pre-operation skin scrub.
  • the commercially available antiseptic scrub HIBICLENS® for example, contains 4% CHX-gluconate.
  • the parent application Ser. No. 14/211,501 and grandparent application Ser. No. 13/529,470 disclose the use of chlorhexidine gluconate in combination with a quarternary ammonium based active ingredient, e.g., benzalkonium chloride.
  • CHX-gluconate is not always desirable in combination, with benzalkonium chloride because of regulatory or other issues. It is desirable, however, in certain instances, to use an antimicrobial composition that does not use CHX-gluconate.
  • benzalkonium chloride when used in combination with certain surfactants may damage the skin or cause irritation that is bothersome to the user. The degree of irritation may depend on the surfactant, but it is problematic in certain instances.
  • benzalkonium chloride in combination with other ingredients that are chosen to be effective and overcome the drawbacks associated when benzalkonium chloride that is used with surfactants may damage or irritate skin. It is desirable to find a composition using benzalkonium chloride that is formulated with a surfactant and other compounds that mitigate this effect of irritating the user's skin, but maintain effectiveness as an antimicrobial without employing CHX-glutonate.
  • an antimicrobial composition includes benzalkonium chloride and a phosphate with glycols such as propylene glycol and triethylene glycol. It includes a polysorbate and a large amount of water, such as over 95% water, to form an aqueous solution that is effective as an antimicrobial and does not harm or irritate the skin.
  • the combination of ingredients work together in an effective manner as an antimicrobial composition.
  • An antimicrobial composition includes benzalkonium chloride in an amount of 0.06% w/w to 0.19% w/w, and cocamidopropyl PG-dimonium chloride phosphate in an amount of 0.6% w/w to 1.9% w/w.
  • Propylene glycol is in an amount of 0.4% w/w to 1.2% w/w and triethylene glycol in an amount of 0.1% w/w to 0.3% w/w.
  • a polysorbate is in an amount of 0.02% w/w to 0.08% w/w, and water is in an amount of 96.0% w/w to 99.0% w/w.
  • the benzalkonium chloride may be in an amount of 0.09% w/w to 0.17% w/w.
  • the cocamidopropyl PG-dimonium chloride phosphate may be in an amount of 0.8% w/w to 1.6% w/w.
  • the propylene glycol may be in an amount of 0.6% w/w to 1.0.% w/w and the triethylene glycol may be in an amount of 0.14% w/w to 0.26% w/w.
  • the polysorbate may be in an amount of 0.04% w/w to 0.06% w/w.
  • the water may be in amount of 97.0% w/w to 98.0% w/w.
  • the polysorbate may comprise polysorbate-20.
  • the benzalkonium chloride may be in an amount of about 0.13% w/w.
  • the cocamidopropyl PG-dimonium chloride phosphate may be in an amount of about 1.25% w/w.
  • the propylene glycol may be in an amount of about 0.8% w/w and the triethylene glycol may be in an amount of about 0.2% w/w.
  • the polysorbate may be in an amount of about 0.05% w/w.
  • the composition overcomes the problems associated when benzalkonium chloride is used with surfactants and the composition may damage or irritate the skin.
  • a specific combination and range of ingredients are used with a specific concentration and range of benzalkonium chloride and formulated to mitigate skin irritation. It has been found that an antimicrobial composition that includes benzalkonium chloride in an amount of 0.06% w/w to 0.19% w/w with specific phosphates, glycols and other components may include a large amount of water and be effective against microbials and not damage skin.
  • the composition includes cocamidopropyl PG-dimonium chloride phosphate in an amount of 0.6% w/w to 1.9% w/w.
  • the composition also includes propylene glycol in an amount of 0.4% w/w to 1.2% w/w. Triethylene glycol is included in an amount of 0.1% w/w to 0.3% w/w. A polysorbate is included in an amount of 0.02% w/w to 0.08% w/w. In an example, the polysorbate is formed as polysorbate-20.
  • the composition may also include trace amounts of a fragrance at around 0.02% w/w to about 0.08% w/w and a color agent such as peach, rose, aqua or other color component that is about 0.05%.
  • the benzalkonium chloride is in an amount of 0.09% w/w to 0.17% w/w and in a preferred example, is about 0.13% w/w.
  • the cocamidopropyl PG-dimonium chloride phosphate is in an amount of 0.08% w/w to 1.6% w/w in an example, and in a preferred example, is about 1.25% w/w.
  • the propylene glycol is in an amount of 0.6% w/w to 1.0% w/w, and in a preferred example, is in an amount of 0.8% w/w.
  • the triethylene glycol is in an amount of 0.14% w/w to 0.26% w/w, and in a preferred example, is about 0.2% w/w.
  • the water is in an amount of about 97.0% w/w to about 98.0% w/w.
  • the polysorbate is in an amount in a preferred example of about 0.05% w/w and is formed as polysorbate-20.
  • the benzalkonium chloride may be supplied as Nobac BZ-K USP NF 50% solution at a preferred amount of about 0.26% by mason.
  • the cocamidopropyl PG-dimonium chloride phosphate may be supplied by Croda as Arlasilk PTC LQ-(AP).
  • the fragrance may be supplied by Cosmo International.
  • the composition has been found effective. It includes the polysorbate, namely, the polysorbate20, and the other ingredients without the chlorhexidine gluconate. It includes the benzalkonium chloride, cocamidopropyl PG-dimonium chloride phosphate, propylene glycol, triethylene glycol, and water.
  • the composition works as an antimicrobial and anti-bacterial with an effectiveness similar to the composition as disclosed in the parent applications that include chlorhexidine gluconate.
  • the polysorbate-20 is about 25-40% by weight of the amount of benzalkonium chloride in an example, and 30-35% in another example. A large amount such as 1.25% by weight of cocamidopropyl PG-dimonium chloride phosphate is used.
  • the polysorbate is an emulsifier and is able to solubolize essential oils into water-based products and is derived from PEG-ylated sorbitan as a derivative of sorbitol and esterified with fatty acids.
  • Polysorbate-20 is also referred to as polyoxyethylene (20) sorbitan monolaurate with the numeral twenty referring to the total number of oxyethylene-(CH 2 CH 2 O)-groups in the molecule. This number twenty following that polysorbate is related to the type of fatty acid associated with the polyoxyethylene sorbitan part of the molecule. The monolaurate is indicated by the number twenty.
  • the polysorbate-20 is a polysorbate surfactant that is stable and has relative nontoxicity.
  • It is operable as a wetting agent and is helpful to prevent non-specific antibody binding that is useful in the antimicrobial composition. It operates with the phosphate of cocamidopropyl PG-dimonium chloride phosphate and is dissolved and operable with the buffer as a wash to remove unbound immunologicals. It may saturate binding sites on surfaces to stabilize a proteins purified protein derivative (PPD) solution and operate as a solubolizing agent of membrane proteins and helpful in antimicrobial compositions.
  • PPD proteins purified protein derivative
  • Benzalkonium chloride operates as a cationic surfactant as a quarternary ammonium compound and organic salt and operates as the biocide and phase transfer agent. It is a surfactant and dissolves the lipid phase and increases drug penetration as an excipient. As noted before, it has efficacy for intermolecular interactions and dissociates cellular membrane lipid bilayers in bacteria and microbials for micellular permeability controls in induced leakage of cellular contents. The enzymes that control many respiratory and metabolic cellular activities are deactivated. It is known that appropriate excipients can greatly enhance the spectrum, performance and detergency and the composition as noted above and meets such difficult standards with minimized deactivation of benzalkonium solutions with organic and inorganic contamination and use as an antimicrobial.
  • the benzalkonium chloride can be provided at USPNF 50% and in a preferred example would be about 2.6% w/w.
  • the benzalkonium chloride and polysorbate-20 operate in conjunction with the cocamidopropyl PG-dimonium chloride phosphate that also operates as a surfactant and to a degree a foam booster. It may operate as a preservative with a moisturizing effect. It is a quarternary ammonium salt with its RCO-group representing a coconut acid moiety.
  • the propylene glycol is about four times greater in w/w concentration than the triethylene glycol and can range from 3:1 to 5:1. It may operate not only as an antimicrobial, but as a solvent to help solvate certain compounds and associated microbials.
  • One aspect is it exerts high levels of biochemical oxygen demand (BOD) during degradation in surface waters and consumes oxygen as an added benefit when microbial populations decompose the propylene glycol.
  • BOD biochemical oxygen demand
  • the triethylene glycol is hygroscopic and dehumidifies fluids. These components interoperate with each other to provide an effective antimicrobial.
  • CHX-gluconate and BAC individually, show excellent antimicrobial effectiveness
  • one of the goals of the research described here was to prepare antimicrobial compositions that use a combination of CHX-gluconate and BAC as the antimicrobial active ingredients, but doing so was difficult.
  • CHX-gluconate is a zwitterion, it tended to precipitate when mixed with BAC, which reduced the antimicrobial effectiveness of CHX-gluconate, thereby defeating the purpose of combining the two ingredients. It was found that, in an aqueous solution containing BAC, CHX-gluconate is stably maintained (i.e. without precipitating over time) by including a phospholipid.
  • a particular phospholipid useful for this purpose was found to be cocamidopropyl PG-dimonium chloride phosphate.
  • the structure of the sodium salt of cocamidopropyl PG-dimonium chloride phosphate is shown below.
  • Cocamidopropyl PG-dimonium chloride phosphate is a phospholipid composed predominantly of diester phosphatides with multiple long alkyl chain groups. It is derived from coconut oil and is said to be compatible with the natural lipids found in the skin's epidermal layers.
  • cocamidopropyl PG-dimonium chloride phosphate behaves as a broad spectrum antimicrobial against mold, gram-positive, and gram-negative bacteria.
  • a preferred cocamidopropyl PG-dimonium chloride phosphate is commercially available from Croda under the name ARALISK PTC.
  • the combination provided a synergistic antimicrobial enhancement. More particularly, the mixture showed a 100 fold enhanced measurement of antimicrobial effectiveness relative to the combined measurements of antimicrobial effectiveness of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate when measured individually.
  • This synergistic enhancement of antimicrobial effectiveness allows for low concentrations of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate to be used in the compositions of the invention without diminishing the antimicrobial effectiveness.
  • % w/w refers to the percent, by weight, of each ingredient relative to the total weight of the composition.
  • an antimicrobial composition of the invention includes the active ingredients and one or more optional ingredients dispersed in an aqueous mixture.
  • the composition includes at least about 60% w/w water, more preferably about 60% w/w to about 99% w/w water, and even more preferably about 65% w/w to about 98% w/w water.
  • the antimicrobial composition includes a stable and antimicrobially effective aqueous blend of at least one chlorhexidine compound, at least one quaternary ammonium compound, and at least one phospholipid compound.
  • stable means that the at least one chlorhexidine compound does not precipitate when exposed to the at least one quaternary ammonium compound.
  • antimicrobially effective describes a composition that inhibits the growth of and/or kills microbes such as bacteria.
  • a stable and antimicrobially effective aqueous blend of these components is achieved when the concentration of the least one chlorhexidine compound is about 0.001% to about 0.2% w/w, the concentration of the least one quaternary ammonium compound is about 0.001% to about 0.3% w/w, and the concentration of the least one phospholipid compound is about 0.5% to about 1.5% w/w.
  • chlorhexidine compounds that may be used in accordance with the invention include, but are not limited to: chlorhexidine free base, chlorhexidine diphosphanilate, chlorhexidine digluconate, chlorhexidine diacetate, chlorhexidine dihydrochloride, chlorhexidine dichloride, chlorhexidine dihydrolodide, chlorhexidine diperchlorate, chlorhexidine dinitrate, chlorhexidine sulfate, chlorhexidine sulfite, chlorhexidine thiosulfate, chlorhexidine di-acid phosphate, chlorhexidine difluorophosphate, chlorhexidine diformate, chlorhexidine dipropionate, chlorhexidine diiodobutyrate, chlorhexidine di-n-valerate, chlorhexidine alcaproate, chlorhexidine malonate, chlorhexidine succinate, chlorhexidine malate, chlorhexidine tartrate, chlorhexidine dimonoglycolate
  • quaternary ammonium compounds that may be used in accordance with the invention include, but are not limited to: benzalkonium chloride (BAC), benzethonium chloride, other benzalkonium or benzethonium halides, cetylpyridinium chloride, degualinium chloride, N-myristyl-N methylmorpholinium methyl sulfate, poly[N-[3-(dimethylammonio)propyl]-N′-[3-(ethyleneoxyethelene dimethylammonio)propyl]urea dichioride], alpha-4-[1-tris (2-hydroxyethyl)ammonium chloride-2-butenyl]-omega-tris(2-hydroxyethyl)ammonium chloride, alpha4 [1-tris(2hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-ome
  • Preferred examples of phospholipids that may be used in accordance with the invention include, but are not limited to: PG-dimonium chloride phosphates such as cocamidopropyl PG-dimonium chloride phosphate.
  • the at least one chlorhexidine compound is preferably chlorhexidine gluconate, the at least one quaternary ammonium compound is benzalkonium chloride, and the at least one phospholipid compound is cocamidopropyl PG-dimonium chloride phosphate.
  • the antimicrobial composition includes an aqueous solution of about 0.001% to about 0.2% w/w chlorhexidine gluconate, about 0.001% to about 0.3% w/w benzalkonium chloride, and about 0.5% to about 1.5% w/w cocamidopropyl PG-dimonium chloride phosphate. It may also include about 0.05% to about 0.5% w/w triethylene glycol and about 0.05% to about 0.8% w/w propylene glycol.
  • the concentration of chlorhexidine gluconate is about 0.2% w/w
  • the concentration of benzalkonium chloride is about 0.13% w/w
  • the concentration of cocamidopropyl PG-dimonium chloride phosphate is about 1.25% w/w.
  • the antimicrobial composition includes an enhanced synergistically effective antimicrobial mixture of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate.
  • the enhanced synergistically effective antimicrobial mixture shows an enhanced measurement of antimicrobial effectiveness relative to the combined measurements of antimicrobial effectiveness of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate when measured individually.
  • Antimicrobial effectiveness may be measured using conventional protocols such as minimum inhibitory concentration testing, bacterial counting, kill time studies, or the like.
  • the preferred concentration of chlorhexidine gluconate is about 0.001% to about 0.2% w/w
  • the preferred concentration of benzalkonium chloride is about 0.001% to about 0.3% w/w
  • the preferred concentration of cocamidopropyl PG-dimonium chloride phosphate about 0.5% to about 1.5% w/w.
  • the concentration of chlorhexidine gluconate is about 0.15% w/w
  • the concentration of benzyalkonium chloride is about 0.13% w/w
  • the concentration of cocamidopropyl PG-dimonium chloride phosphate is about 1.25% w/w.
  • the composition may also include about 0.05% w/w to about 0.5% w/w triethylene glycol and 0.05% w/w to about 0.8% w/w propylene glycol.
  • the pH of the antimicrobial composition is preferably maintained between about 3 and about 9, more preferably between about 5 and about 8.
  • Quaternary ammonium compounds are typically unstable below pH 3 or above pH 9, and are usually incompatible with anionic soaps and with moderate concentrations of anionic detergents. In particular, anionic soaps and surfactants have been found to neutralize quaternary ammonium compounds.
  • one or more preservatives may be added to the antimicrobial composition, in order to preserve the antimicrobial active ingredients.
  • the most commonly used preservatives in conventional pharmaceutical formulations are the parabens (including, but not limited to methyl, ethyl, propyl, pentyl, hexyl and heptyl paraben), and phenoxyethanol.
  • preservatives which act as formaldehyde donors including diazolidinyl urea, imidazolidinyl urea, among others.
  • the thickener may be used for the stabilization of the final composition, and for the regulation of viscosity, which may vary widely according to the desired application.
  • thickeners include, but are not limited to methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcellulose and methyl cellulose, and lysophosphatidic acid.
  • polyol co-solvent Another optional ingredient that can be included in the compositions is a polyol co-solvent. This can be conveniently added for the dissolution or stabilization of certain ingredients.
  • the polyol co-solvent is preferably selected from the glycol class of compounds.
  • Preferred glycols include propylene glycol, polyethylene glycol, and triethylene glycol.
  • Such polyethylene glycols include the polyalkene glycol products with chemical structures having 2-3 carbons in the alkene moiety, and a mean molecular weight ranging from 200-4000.
  • These compounds are present in amounts generally ranging from about 0.01% w/w to about 15.0% w/w, based on the total weight of the composition, or more preferably from about 0.05% w/w weight percent to about 1.0% w/w percent.
  • pH adjusting compounds may be included. Such pH adjusting compounds may be organic or inorganic acids and bases alone or in combination with their respective salts. Commonly used pH lowering agents are citric acid, sorbic acid, ascorbic acid, malic acid, and succinic acid among many others. Commonly used pH raising agents agents include triethanolamine, ammonium hydroxide, potassium hydroxide, sodium hydroxide, and other hydroxides. The amount of the pH adjusting compound used is the amount needed to adjust the pH to the desired value.
  • the antimicrobial compositions of the invention are preferably used as instant hand sanitizers. Accordingly, they may be packaged in dispensing bottles and dispensed onto the hands of a user. They are preferably present in a form that is antimicrobial when applied topically to skin. Suitable forms for topical application include, but are not limited to creams, gels, suspensions, or the like.
  • the antimicrobial compositions are particularly useful to sanitize hands in situations where conventional soap and water hand washing facilities are not available or are impractical to use.
  • the antimicrobial composition is used to sanitize the skin of a subject in need thereof by applying an effective amount of the antimicrobial composition to the subject.
  • an “effective amount” is an amount that is sufficient to affect a microbe, such as by inhibiting microbial growth or killing the microbe.
  • the subject may dispense the antimicrobial composition onto the subject's hands and rub the hands together.
  • antimicrobial compositions include, but are not limited to: formulations for oral use such as a mouthwash or dentifrice; formulations for topical, use such as a skin sanitizer, surgical scrub and preparation, and handwash; treatment of infections of the skin or mouth area in a human; veterinary medicament for animal skin, hooves, claws, fur, or teeth; nail paints and polishes; indwelling medical devices; venous access catheters; gastric and enteric long term feeding tubes; neurological shunting tubing; polytetrafluoroethane graft materials (both for tissue patch and vascular conduits); endotracheal and tracheostomy tubing; intravenous interarterial tubing; indwelling urinary catheters; joint implants; soft tissue implants, orthopaedic external fixation devices, (including hardware necessary to secure them to the bone); medication ampules; intravenous polyethylene fluid storage/delivery bag systems (including those for blood and blood products); mouth rinses (
  • the antimicrobial composition may also be used in formulations not intended for application or administration directly to a subject, such as, for example, as a surface, air, or water sanitizer.
  • This example shows how an antimicrobial composition was prepared in accordance with the invention.
  • the antimicrobial composition prepared in this example contained: 0.15% w/w chlorhexidine gluconate; 0.13% w/w benzalkonium chloride; 1.25% w/w cocamidopropyl PG-dimonium chloride; 0.2% w/w triethylene glycol; 0.8% propylene glycol; and 96.6% deionized water.
  • composition was prepared by using commercially available materials.
  • UNIQUAT QAC 80 (Lonza) was the source of the BAC.
  • ARLASILK PTC was the source of the cocamidopropyl PG-dimonium chloride.
  • This example shows how the stability testing was performed and how stable compositions were identified.
  • the samples were subjected to three consecutive freeze/thaw cycles over a five day period.
  • the freezing temperature was ⁇ 14 Celsius and the thawing temperature was 37 Celsius.
  • Stability was assessed by visually inspecting each sample for the formation of a precipitate and/or discoloration.
  • concentration ranges for the various ingredients for the stable samples were: about 0.001% to about 0.15% w/w chlorhexidine gluconate; about 0.001% to about 0.3% w/w benzalkonium chloride; about 0.5% to about 1.5% w/w cocamidopropyl PG-dimonium chloride phosphate; about 0.05% w/w to about 0.5% w/w triethylene glycol; and about 0.05% w/w to about 0.8% w/w propylene glycol.
  • This example shows how the antimicrobial effectiveness of certain antimicrobial compositions prepared in accordance with the invention was tested and describes the unexpected result that CHX-Gluconate, BAC, and cocamidopropyl PG-dimonium chloride phosphate synergistically enhance the antimicrobial effectives when compared to the antimicrobial effectiveness of each of these tested individually.
  • the tests were performed on broth cultures that were passed through at least three consecutive daily transfers but no more than ten daily transfers.
  • the broth cultures were diluted with the appropriate broth to obtain an inoculum count of 6 ⁇ 10 8 to 1 ⁇ 10 9 CFU/ml (Mac Farland Standard ⁇ 2.0 to 3.0).
  • the test article was used undiluted.
  • the exposure time and temperature was 15 seconds at 25 ⁇ 1° C., respectively. All tests involving the test article were conducted in triplicate.
  • a 4.95 gram sample of the test article was placed in a sterile, screw-top 50 ml polyethylene tube at 25 ⁇ 1° C.
  • the test article was inoculated with 0.05 ml of the test organism at the appropriate concentration.
  • the tube contents were neutralized by the addition of 45 ml of neutralizer (Tryptic or Trypticase Soy Broth (TSB) with 10% TWEEN 80, 3% Lecithin, 0.5% Sodium thiosulfate and 0.1% Histidine, pH 7.2 ⁇ 0.1) followed by vortexing.
  • TBS Trypticase Soy Broth
  • One ml of the neutralized sample (10 ⁇ 1 dilution) was serially diluted in 10 -fold steps to 10 ⁇ 6 for the test article and to 10 ⁇ 7 for the numbers control using tubes containing 9 ml of AOAC Neutralizer blanks.
  • An inoculum count was determined by 10-fold serial dilutions to 10 ⁇ 8 using tubes containing 9 ml of AOAC phosphate buffered dilution water.
  • the dilutions were plated in duplicate on Letheen Agar, and plates were incubated in an inverted position for the appropriate time and at a temperature appropriate for the test organism
  • Antimicrobial effectiveness was determined by calculating the log reduction of bacteria in the test sample. For comparison, the log reduction for a 0.02% CHX-gluconate solution is 0.5, the log reduction for a 0.13% BAC solution is 0.5, and the log reduction for a 1% cocamidopropyl PG-dimonium chloride phosphate solution is 2. When added together, the total log reduction for the three ingredients tested individually is 3.
  • an antimicrobial composition composed of 0.02% CHX-gluconate, 0.13% BAC, 1% cocamidopropyl PG-dimonium chloride phosphate, 0.2% triethylene glycol, and 0.2% propylene glycol provided a log reduction of 5, which is a 100 fold increase in the antimicrobial effectiveness.
  • the antimicrobial compositions of the invention include an enhanced synergistically effective antimicrobial mixture of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate.

Abstract

Provided are alcohol-free antimicrobial compositions comprising benzalkonium chloride, antimicrobial phospholipid, water, and optionally, polyol co-solvent and/or surfactant. Also provided are alcohol-free antimicrobial compositions comprising quaternary ammonium salt, polyol co-solvent and/or surfactant, and water. Preferably, the compositions are formulated for use as a skin sanitizer.

Description

    RELATED APPLICATIONS
  • This is a continuation application of Ser. No. 14/968, 959 filed Dec. 15, 2015, which is a continuation-in-part application of Ser. No. 14/211,501 filed Mar. 14, 2014 (abandoned), which is a continuation-in-part application of Ser. No. 13/529,470 filed Jun. 21, 2012 (abandoned), which claimed priority to provisional application Ser. No. 61/499,265, filed Jun. 21, 2011, the disclosures which are hereby incorporated by reference in their entirety.
  • FIELD OF THE INVENTION
  • The invention relates to antimicrobial compositions, and more particularly, to antimicrobial compositions that use quaternary ammonium based active ingredients, such as benzalkonium chloride in combination with phospholipids and glycols.
  • BACKGROUND
  • The wide variety of instant hand sanitizers available to consumers may be grouped into two categories: alcohol-free and alcohol-containing. Of the former category, quaternary ammonium compounds are most frequently employed as the antimicrobial active ingredient. Of the latter category, ethanol at a concentration range of 62-70% w/w is most readily available on the market. In general, both alcohol-free and alcohol-containing products are effective at reducing germs on the skin with a single use. With repeated use, however, alcohol-free products show a significant persistence of antimicrobial activity while alcohol-containing products appear to increase the skin's ability to carry disease-causing pathogens.
  • An antimicrobial active ingredient that has been used to sanitize hands is chlorhexidine (CHX). In one aspect, chlorhexidine gluconate (CHX-gluconate), a particular salt of chlorhexidine and gluconate, is widely used as a surgical hand scrub and pre-operation skin scrub. The commercially available antiseptic scrub HIBICLENS®, for example, contains 4% CHX-gluconate.
  • The parent application Ser. No. 14/211,501 and grandparent application Ser. No. 13/529,470 disclose the use of chlorhexidine gluconate in combination with a quarternary ammonium based active ingredient, e.g., benzalkonium chloride. CHX-gluconate is not always desirable in combination, with benzalkonium chloride because of regulatory or other issues. It is desirable, however, in certain instances, to use an antimicrobial composition that does not use CHX-gluconate. It has also been, found, that benzalkonium chloride when used in combination with certain surfactants may damage the skin or cause irritation that is bothersome to the user. The degree of irritation may depend on the surfactant, but it is problematic in certain instances. It is also desirable to use benzalkonium chloride in combination with other ingredients that are chosen to be effective and overcome the drawbacks associated when benzalkonium chloride that is used with surfactants may damage or irritate skin. It is desirable to find a composition using benzalkonium chloride that is formulated with a surfactant and other compounds that mitigate this effect of irritating the user's skin, but maintain effectiveness as an antimicrobial without employing CHX-glutonate.
  • SUMMARY
  • According to one aspect of the invention, an antimicrobial composition includes benzalkonium chloride and a phosphate with glycols such as propylene glycol and triethylene glycol. It includes a polysorbate and a large amount of water, such as over 95% water, to form an aqueous solution that is effective as an antimicrobial and does not harm or irritate the skin. The combination of ingredients work together in an effective manner as an antimicrobial composition.
  • An antimicrobial composition includes benzalkonium chloride in an amount of 0.06% w/w to 0.19% w/w, and cocamidopropyl PG-dimonium chloride phosphate in an amount of 0.6% w/w to 1.9% w/w. Propylene glycol is in an amount of 0.4% w/w to 1.2% w/w and triethylene glycol in an amount of 0.1% w/w to 0.3% w/w. A polysorbate is in an amount of 0.02% w/w to 0.08% w/w, and water is in an amount of 96.0% w/w to 99.0% w/w.
  • The benzalkonium chloride may be in an amount of 0.09% w/w to 0.17% w/w. The cocamidopropyl PG-dimonium chloride phosphate may be in an amount of 0.8% w/w to 1.6% w/w. The propylene glycol may be in an amount of 0.6% w/w to 1.0.% w/w and the triethylene glycol may be in an amount of 0.14% w/w to 0.26% w/w. The polysorbate may be in an amount of 0.04% w/w to 0.06% w/w. The water may be in amount of 97.0% w/w to 98.0% w/w.
  • In an example, the polysorbate, may comprise polysorbate-20. The benzalkonium chloride may be in an amount of about 0.13% w/w. The cocamidopropyl PG-dimonium chloride phosphate may be in an amount of about 1.25% w/w. The propylene glycol may be in an amount of about 0.8% w/w and the triethylene glycol may be in an amount of about 0.2% w/w. The polysorbate may be in an amount of about 0.05% w/w.
  • DETAILED DESCRIPTION
  • In the Summary above and in the Detailed Description, reference is made to particular features (including method steps) of the invention. It is to be understood that the disclosure of the invention in this specification includes all possible combinations of such particular features. For example, where a particular feature is disclosed in the context of a particular aspect or embodiment of the invention, that feature can also be used, to the extent possible, in combination with and/or in the context of other particular aspects and embodiments of the invention, and in the invention generally.
  • The term “comprises” is used herein to mean that other ingredients, features, steps, etc. are optionally present. When reference is made herein to a method comprising two or more defined steps, the steps can be carried in any order or simultaneously (except where the context excludes that possibility), and the method can include one or more steps which are carried out before any of the defined steps, between two of the defined steps, or after all of the defined steps (except where the context excludes that possibility).
  • In this section, the invention will be described more fully with reference to certain preferred embodiments. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will convey preferred embodiments of the invention to those skilled in the art.
  • The composition overcomes the problems associated when benzalkonium chloride is used with surfactants and the composition may damage or irritate the skin. A specific combination and range of ingredients are used with a specific concentration and range of benzalkonium chloride and formulated to mitigate skin irritation. It has been found that an antimicrobial composition that includes benzalkonium chloride in an amount of 0.06% w/w to 0.19% w/w with specific phosphates, glycols and other components may include a large amount of water and be effective against microbials and not damage skin. In an example, the composition includes cocamidopropyl PG-dimonium chloride phosphate in an amount of 0.6% w/w to 1.9% w/w. The composition also includes propylene glycol in an amount of 0.4% w/w to 1.2% w/w. Triethylene glycol is included in an amount of 0.1% w/w to 0.3% w/w. A polysorbate is included in an amount of 0.02% w/w to 0.08% w/w. In an example, the polysorbate is formed as polysorbate-20. The composition may also include trace amounts of a fragrance at around 0.02% w/w to about 0.08% w/w and a color agent such as peach, rose, aqua or other color component that is about 0.05%.
  • In an example, the benzalkonium chloride is in an amount of 0.09% w/w to 0.17% w/w and in a preferred example, is about 0.13% w/w. The cocamidopropyl PG-dimonium chloride phosphate is in an amount of 0.08% w/w to 1.6% w/w in an example, and in a preferred example, is about 1.25% w/w. The propylene glycol is in an amount of 0.6% w/w to 1.0% w/w, and in a preferred example, is in an amount of 0.8% w/w. The triethylene glycol is in an amount of 0.14% w/w to 0.26% w/w, and in a preferred example, is about 0.2% w/w.
  • The water is in an amount of about 97.0% w/w to about 98.0% w/w. The polysorbate is in an amount in a preferred example of about 0.05% w/w and is formed as polysorbate-20. In an example, the benzalkonium chloride may be supplied as Nobac BZ-K USP NF 50% solution at a preferred amount of about 0.26% by mason. The cocamidopropyl PG-dimonium chloride phosphate may be supplied by Croda as Arlasilk PTC LQ-(AP). The fragrance may be supplied by Cosmo International.
  • The composition has been found effective. It includes the polysorbate, namely, the polysorbate20, and the other ingredients without the chlorhexidine gluconate. It includes the benzalkonium chloride, cocamidopropyl PG-dimonium chloride phosphate, propylene glycol, triethylene glycol, and water. The composition works as an antimicrobial and anti-bacterial with an effectiveness similar to the composition as disclosed in the parent applications that include chlorhexidine gluconate.
  • Removing the chlorhexidine gluconate and maintaining the benzalkonium chloride, cocamidopropyl PG-dimonium chloride phosphate, propylene glycol, triethylene glycol, and large amount of water together with the polysorbate-20 has been found effective and safe. The polysorbate-20 is about 25-40% by weight of the amount of benzalkonium chloride in an example, and 30-35% in another example. A large amount such as 1.25% by weight of cocamidopropyl PG-dimonium chloride phosphate is used. The polysorbate is an emulsifier and is able to solubolize essential oils into water-based products and is derived from PEG-ylated sorbitan as a derivative of sorbitol and esterified with fatty acids. Polysorbate-20 is also referred to as polyoxyethylene (20) sorbitan monolaurate with the numeral twenty referring to the total number of oxyethylene-(CH2CH2O)-groups in the molecule. This number twenty following that polysorbate is related to the type of fatty acid associated with the polyoxyethylene sorbitan part of the molecule. The monolaurate is indicated by the number twenty. The polysorbate-20 is a polysorbate surfactant that is stable and has relative nontoxicity. It is operable as a wetting agent and is helpful to prevent non-specific antibody binding that is useful in the antimicrobial composition. It operates with the phosphate of cocamidopropyl PG-dimonium chloride phosphate and is dissolved and operable with the buffer as a wash to remove unbound immunologicals. It may saturate binding sites on surfaces to stabilize a proteins purified protein derivative (PPD) solution and operate as a solubolizing agent of membrane proteins and helpful in antimicrobial compositions.
  • Benzalkonium chloride operates as a cationic surfactant as a quarternary ammonium compound and organic salt and operates as the biocide and phase transfer agent. It is a surfactant and dissolves the lipid phase and increases drug penetration as an excipient. As noted before, it has efficacy for intermolecular interactions and dissociates cellular membrane lipid bilayers in bacteria and microbials for micellular permeability controls in induced leakage of cellular contents. The enzymes that control many respiratory and metabolic cellular activities are deactivated. It is known that appropriate excipients can greatly enhance the spectrum, performance and detergency and the composition as noted above and meets such difficult standards with minimized deactivation of benzalkonium solutions with organic and inorganic contamination and use as an antimicrobial.
  • In an example, the benzalkonium chloride can be provided at USPNF 50% and in a preferred example would be about 2.6% w/w. The benzalkonium chloride and polysorbate-20 operate in conjunction with the cocamidopropyl PG-dimonium chloride phosphate that also operates as a surfactant and to a degree a foam booster. It may operate as a preservative with a moisturizing effect. It is a quarternary ammonium salt with its RCO-group representing a coconut acid moiety. it may operate as a counter-irritant from anionic surfactants and is not adversely effected by solution pH, anionic or non-ionic surfactants or preservatives, thus, making it operable not only with the benzalkonium chloride and polysorbate-20, but also with the propylene glycol and triethylene glycol and soluble with the water. It may appear that the use of the propylene glycol and triethylene glycol are mutually exclusive of each other and with the other components, but in operation, the components as described is effective. The propylene glycol is about four times greater in w/w concentration than the triethylene glycol and can range from 3:1 to 5:1. It may operate not only as an antimicrobial, but as a solvent to help solvate certain compounds and associated microbials. One aspect is it exerts high levels of biochemical oxygen demand (BOD) during degradation in surface waters and consumes oxygen as an added benefit when microbial populations decompose the propylene glycol. The triethylene glycol is hygroscopic and dehumidifies fluids. These components interoperate with each other to provide an effective antimicrobial.
  • There now follows a description of the composition as described in the parent and grandparent applications using the chlorhexidine gluconate, benzalkonium chloride and other components such as the cocamidopropyl PG-dimonium chloride phosphate.
  • Since CHX-gluconate and BAC, individually, show excellent antimicrobial effectiveness, one of the goals of the research described here was to prepare antimicrobial compositions that use a combination of CHX-gluconate and BAC as the antimicrobial active ingredients, but doing so was difficult. Because CHX-gluconate is a zwitterion, it tended to precipitate when mixed with BAC, which reduced the antimicrobial effectiveness of CHX-gluconate, thereby defeating the purpose of combining the two ingredients. It was found that, in an aqueous solution containing BAC, CHX-gluconate is stably maintained (i.e. without precipitating over time) by including a phospholipid. Although not intended to be limiting, a particular phospholipid useful for this purpose was found to be cocamidopropyl PG-dimonium chloride phosphate. The structure of the sodium salt of cocamidopropyl PG-dimonium chloride phosphate is shown below.
  • Figure US20180255781A1-20180913-C00001
  • Cocamidopropyl PG-dimonium chloride phosphate is a phospholipid composed predominantly of diester phosphatides with multiple long alkyl chain groups. It is derived from coconut oil and is said to be compatible with the natural lipids found in the skin's epidermal layers. Advantageously, cocamidopropyl PG-dimonium chloride phosphate behaves as a broad spectrum antimicrobial against mold, gram-positive, and gram-negative bacteria. A published 2004 report by Uniqema Personal Care in Business Briefing: Global Cosmetics Manufacturing at pages 1-4, which is hereby incorporated by reference in its entirety, describes additional details about cocamidopropyl PG-dimonium chloride phosphate. As of the date this application was filed, this reference was available online at: http://www.touchbriefings.com/pdf/846/Uniqema.pdf. A preferred cocamidopropyl PG-dimonium chloride phosphate is commercially available from Croda under the name ARALISK PTC.
  • Remarkably, it was unexpectedly discovered that the when CHX-gluconate, BAC, and a phospholipid, were mixed to make the antimicrobial composition, the combination provided a synergistic antimicrobial enhancement. More particularly, the mixture showed a 100 fold enhanced measurement of antimicrobial effectiveness relative to the combined measurements of antimicrobial effectiveness of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate when measured individually. This synergistic enhancement of antimicrobial effectiveness allows for low concentrations of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate to be used in the compositions of the invention without diminishing the antimicrobial effectiveness.
  • Preferred concentrations of the various ingredients will now be discussed with respect to % w/w, which refers to the percent, by weight, of each ingredient relative to the total weight of the composition.
  • Certain preferred embodiments of the antimicrobial compositions are now described. In general, an antimicrobial composition of the invention includes the active ingredients and one or more optional ingredients dispersed in an aqueous mixture. Preferably the composition includes at least about 60% w/w water, more preferably about 60% w/w to about 99% w/w water, and even more preferably about 65% w/w to about 98% w/w water.
  • In a preferred embodiment, the antimicrobial composition includes a stable and antimicrobially effective aqueous blend of at least one chlorhexidine compound, at least one quaternary ammonium compound, and at least one phospholipid compound. The term “stable” means that the at least one chlorhexidine compound does not precipitate when exposed to the at least one quaternary ammonium compound. The phrase “antimicrobially effective” describes a composition that inhibits the growth of and/or kills microbes such as bacteria.
  • Through experimentation, it was discovered that a stable and antimicrobially effective aqueous blend of these components is achieved when the concentration of the least one chlorhexidine compound is about 0.001% to about 0.2% w/w, the concentration of the least one quaternary ammonium compound is about 0.001% to about 0.3% w/w, and the concentration of the least one phospholipid compound is about 0.5% to about 1.5% w/w.
  • Preferred examples of chlorhexidine compounds that may be used in accordance with the invention include, but are not limited to: chlorhexidine free base, chlorhexidine diphosphanilate, chlorhexidine digluconate, chlorhexidine diacetate, chlorhexidine dihydrochloride, chlorhexidine dichloride, chlorhexidine dihydrolodide, chlorhexidine diperchlorate, chlorhexidine dinitrate, chlorhexidine sulfate, chlorhexidine sulfite, chlorhexidine thiosulfate, chlorhexidine di-acid phosphate, chlorhexidine difluorophosphate, chlorhexidine diformate, chlorhexidine dipropionate, chlorhexidine diiodobutyrate, chlorhexidine di-n-valerate, chlorhexidine alcaproate, chlorhexidine malonate, chlorhexidine succinate, chlorhexidine malate, chlorhexidine tartrate, chlorhexidine dimonoglycolate, chlorhexidine monodiglycolate, chlorhexidine dilactate, chlorhexidine chlorhexidine di-isothionate, chlorhexidine dibenzoate, chlorhexidine dicinnamate, chlorhexidine dimandelate, chlorhexidine di-isophthalate, chlorhexidine di-2hydroxynapthoate, and chlorhexidine embonate. As discussed above, a particularly preferred example is chlorhexidine gluconate.
  • Preferred examples of quaternary ammonium compounds that may be used in accordance with the invention include, but are not limited to: benzalkonium chloride (BAC), benzethonium chloride, other benzalkonium or benzethonium halides, cetylpyridinium chloride, degualinium chloride, N-myristyl-N methylmorpholinium methyl sulfate, poly[N-[3-(dimethylammonio)propyl]-N′-[3-(ethyleneoxyethelene dimethylammonio)propyl]urea dichioride], alpha-4-[1-tris (2-hydroxyethyl)ammonium chloride-2-butenyl]-omega-tris(2-hydroxyethyl)ammonium chloride, alpha4 [1-tris(2hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-omega-tris(2hydroxyethyl) ammonium chloride, poly[oxyethylene(dimethyliminio)ethylene(dimethyliminio)-ethylene dichloride], ethyl hexadecyl dimethyl ammonium ethyl sulfate, dimethyl ammonium ethyl sulfate, dimethylethyl-benzyl ammonium chloride, dimethylbenzyl ammonium chloride, cetyldimethylethyl ammonium, bromide, monoalkyltrimethyl ammonium salts, dialkyldimethyl ammonium salts, heteroaromatic ammonium salts, polysubstituted quaternary ammonium salts, bis-quaternary ammonium salts, and polymeric quaternary ammonium salts, n-alkyl dialkyl benzyl ammonium chlorides, n-alkyl (C12, C14, C16) dimethyl benzyl ammonium chloride and organosilicon-substituted quaternary ammonium compounds such as 3-(trimethoxysilyl propyloctadecyldimethyl ammonium chloride.
  • Preferred examples of phospholipids that may be used in accordance with the invention include, but are not limited to: PG-dimonium chloride phosphates such as cocamidopropyl PG-dimonium chloride phosphate.
  • In such embodiments, the at least one chlorhexidine compound is preferably chlorhexidine gluconate, the at least one quaternary ammonium compound is benzalkonium chloride, and the at least one phospholipid compound is cocamidopropyl PG-dimonium chloride phosphate.
  • In another preferred embodiment, the antimicrobial composition includes an aqueous solution of about 0.001% to about 0.2% w/w chlorhexidine gluconate, about 0.001% to about 0.3% w/w benzalkonium chloride, and about 0.5% to about 1.5% w/w cocamidopropyl PG-dimonium chloride phosphate. It may also include about 0.05% to about 0.5% w/w triethylene glycol and about 0.05% to about 0.8% w/w propylene glycol. In an even more particular example of this embodiment, the concentration of chlorhexidine gluconate is about 0.2% w/w, the concentration of benzalkonium chloride is about 0.13% w/w, and the concentration of cocamidopropyl PG-dimonium chloride phosphate is about 1.25% w/w.
  • In another preferred embodiment, the antimicrobial composition includes an enhanced synergistically effective antimicrobial mixture of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate. Here, the enhanced synergistically effective antimicrobial mixture shows an enhanced measurement of antimicrobial effectiveness relative to the combined measurements of antimicrobial effectiveness of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate when measured individually. Antimicrobial effectiveness may be measured using conventional protocols such as minimum inhibitory concentration testing, bacterial counting, kill time studies, or the like.
  • In this embodiment, the preferred concentration of chlorhexidine gluconate is about 0.001% to about 0.2% w/w, the preferred concentration of benzalkonium chloride is about 0.001% to about 0.3% w/w, and the preferred concentration of cocamidopropyl PG-dimonium chloride phosphate about 0.5% to about 1.5% w/w. In a more particular example, the concentration of chlorhexidine gluconate is about 0.15% w/w, the concentration of benzyalkonium chloride is about 0.13% w/w, and the concentration of cocamidopropyl PG-dimonium chloride phosphate is about 1.25% w/w. The composition may also include about 0.05% w/w to about 0.5% w/w triethylene glycol and 0.05% w/w to about 0.8% w/w propylene glycol.
  • The pH of the antimicrobial composition is preferably maintained between about 3 and about 9, more preferably between about 5 and about 8. Quaternary ammonium compounds are typically unstable below pH 3 or above pH 9, and are usually incompatible with anionic soaps and with moderate concentrations of anionic detergents. In particular, anionic soaps and surfactants have been found to neutralize quaternary ammonium compounds.
  • Optionally one or more preservatives may be added to the antimicrobial composition, in order to preserve the antimicrobial active ingredients. The most commonly used preservatives in conventional pharmaceutical formulations are the parabens (including, but not limited to methyl, ethyl, propyl, pentyl, hexyl and heptyl paraben), and phenoxyethanol. Preferably excluded from the embodiments of the invention are preservatives which act as formaldehyde donors, including diazolidinyl urea, imidazolidinyl urea, among others.
  • Another optional ingredient that can be included in the antimicrobial composition is a thickener. The thickener may be used for the stabilization of the final composition, and for the regulation of viscosity, which may vary widely according to the desired application. Examples of thickeners include, but are not limited to methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcellulose and methyl cellulose, and lysophosphatidic acid.
  • Another optional ingredient that can be included in the compositions is a polyol co-solvent. This can be conveniently added for the dissolution or stabilization of certain ingredients. The polyol co-solvent is preferably selected from the glycol class of compounds. Preferred glycols include propylene glycol, polyethylene glycol, and triethylene glycol. Such polyethylene glycols include the polyalkene glycol products with chemical structures having 2-3 carbons in the alkene moiety, and a mean molecular weight ranging from 200-4000. These compounds, if used, are present in amounts generally ranging from about 0.01% w/w to about 15.0% w/w, based on the total weight of the composition, or more preferably from about 0.05% w/w weight percent to about 1.0% w/w percent.
  • If desired, one or more pH adjusting compounds may be included. Such pH adjusting compounds may be organic or inorganic acids and bases alone or in combination with their respective salts. Commonly used pH lowering agents are citric acid, sorbic acid, ascorbic acid, malic acid, and succinic acid among many others. Commonly used pH raising agents agents include triethanolamine, ammonium hydroxide, potassium hydroxide, sodium hydroxide, and other hydroxides. The amount of the pH adjusting compound used is the amount needed to adjust the pH to the desired value.
  • The antimicrobial compositions of the invention are preferably used as instant hand sanitizers. Accordingly, they may be packaged in dispensing bottles and dispensed onto the hands of a user. They are preferably present in a form that is antimicrobial when applied topically to skin. Suitable forms for topical application include, but are not limited to creams, gels, suspensions, or the like. The antimicrobial compositions are particularly useful to sanitize hands in situations where conventional soap and water hand washing facilities are not available or are impractical to use.
  • In a preferred method of use aspect of the invention, the antimicrobial composition is used to sanitize the skin of a subject in need thereof by applying an effective amount of the antimicrobial composition to the subject. Here, an “effective amount” is an amount that is sufficient to affect a microbe, such as by inhibiting microbial growth or killing the microbe. In practice, the subject may dispense the antimicrobial composition onto the subject's hands and rub the hands together.
  • Other exemplary uses for the antimicrobial compositions include, but are not limited to: formulations for oral use such as a mouthwash or dentifrice; formulations for topical, use such as a skin sanitizer, surgical scrub and preparation, and handwash; treatment of infections of the skin or mouth area in a human; veterinary medicament for animal skin, hooves, claws, fur, or teeth; nail paints and polishes; indwelling medical devices; venous access catheters; gastric and enteric long term feeding tubes; neurological shunting tubing; polytetrafluoroethane graft materials (both for tissue patch and vascular conduits); endotracheal and tracheostomy tubing; intravenous interarterial tubing; indwelling urinary catheters; joint implants; soft tissue implants, orthopaedic external fixation devices, (including hardware necessary to secure them to the bone); medication ampules; intravenous polyethylene fluid storage/delivery bag systems (including those for blood and blood products); mouth rinses (including swish and swallow preparations); skin preparations; bowel preparations; footwear inserts; and towelettes.
  • The antimicrobial composition may also be used in formulations not intended for application or administration directly to a subject, such as, for example, as a surface, air, or water sanitizer.
  • EXAMPLES
  • The following examples are provided for the purpose of illustration and do not limit the scope of the invention in any way.
  • Example 1 Preparation of an Exemplary Antimicrobial Composition
  • This example shows how an antimicrobial composition was prepared in accordance with the invention.
  • The antimicrobial composition prepared in this example contained: 0.15% w/w chlorhexidine gluconate; 0.13% w/w benzalkonium chloride; 1.25% w/w cocamidopropyl PG-dimonium chloride; 0.2% w/w triethylene glycol; 0.8% propylene glycol; and 96.6% deionized water.
  • The composition was prepared by using commercially available materials. UNIQUAT QAC 80 (Lonza) was the source of the BAC. ARLASILK PTC was the source of the cocamidopropyl PG-dimonium chloride.
  • Example 2 Stability Testing
  • This example shows how the stability testing was performed and how stable compositions were identified.
  • In these experiments, numerous combinations of CHX-gluconate and BAC were tested to determine the combinations and concentrations that yielded stable antimicrobial compositions. It was discovered that cocamidopropyl PG-dimonium chloride phosphate was effective as a CHX-gluconate stabilizer. As described previously, a stable composition is one for which CHX-gluconate did not precipitate over time.
  • The samples were subjected to three consecutive freeze/thaw cycles over a five day period. The freezing temperature was −14 Celsius and the thawing temperature was 37 Celsius. Stability was assessed by visually inspecting each sample for the formation of a precipitate and/or discoloration.
  • The concentration ranges for the various ingredients for the stable samples were: about 0.001% to about 0.15% w/w chlorhexidine gluconate; about 0.001% to about 0.3% w/w benzalkonium chloride; about 0.5% to about 1.5% w/w cocamidopropyl PG-dimonium chloride phosphate; about 0.05% w/w to about 0.5% w/w triethylene glycol; and about 0.05% w/w to about 0.8% w/w propylene glycol.
  • Example 3 Antimicrobial Effectiveness Testing
  • This example shows how the antimicrobial effectiveness of certain antimicrobial compositions prepared in accordance with the invention was tested and describes the unexpected result that CHX-Gluconate, BAC, and cocamidopropyl PG-dimonium chloride phosphate synergistically enhance the antimicrobial effectives when compared to the antimicrobial effectiveness of each of these tested individually.
  • The tests were performed on broth cultures that were passed through at least three consecutive daily transfers but no more than ten daily transfers. The broth cultures were diluted with the appropriate broth to obtain an inoculum count of 6×108 to 1×109 CFU/ml (Mac Farland Standard ˜2.0 to 3.0). The test article was used undiluted. The exposure time and temperature was 15 seconds at 25±1° C., respectively. All tests involving the test article were conducted in triplicate. A 4.95 gram sample of the test article was placed in a sterile, screw-top 50 ml polyethylene tube at 25±1° C. The test article was inoculated with 0.05 ml of the test organism at the appropriate concentration. The tube contents were neutralized by the addition of 45 ml of neutralizer (Tryptic or Trypticase Soy Broth (TSB) with 10% TWEEN 80, 3% Lecithin, 0.5% Sodium thiosulfate and 0.1% Histidine, pH 7.2±0.1) followed by vortexing. One ml of the neutralized sample (10−1 dilution) was serially diluted in 10-fold steps to 10−6 for the test article and to 10−7 for the numbers control using tubes containing 9 ml of AOAC Neutralizer blanks. An inoculum count was determined by 10-fold serial dilutions to 10−8 using tubes containing 9 ml of AOAC phosphate buffered dilution water. The dilutions were plated in duplicate on Letheen Agar, and plates were incubated in an inverted position for the appropriate time and at a temperature appropriate for the test organism. The test organism was a single species of Staphylococcus aureus.
  • Antimicrobial effectiveness was determined by calculating the log reduction of bacteria in the test sample. For comparison, the log reduction for a 0.02% CHX-gluconate solution is 0.5, the log reduction for a 0.13% BAC solution is 0.5, and the log reduction for a 1% cocamidopropyl PG-dimonium chloride phosphate solution is 2. When added together, the total log reduction for the three ingredients tested individually is 3.
  • Our results showed that an antimicrobial composition composed of 0.02% CHX-gluconate, 0.13% BAC, 1% cocamidopropyl PG-dimonium chloride phosphate, 0.2% triethylene glycol, and 0.2% propylene glycol provided a log reduction of 5, which is a 100 fold increase in the antimicrobial effectiveness. This indicates that the antimicrobial compositions of the invention include an enhanced synergistically effective antimicrobial mixture of chlorhexidine gluconate, benzalkonium chloride, and cocamidopropyl PG-dimonium chloride phosphate.
  • The invention has been described above with reference to preferred embodiments. Unless otherwise defined, all technical and scientific terms used herein are intended to have the same meaning as commonly understood in the art to which this invention pertains and at the time of its filing. Although various methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described. However, the skilled should understand that the methods and materials used and described are examples and may not be the only ones suitable for use in the invention.
  • Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough, complete, and will fully convey the scope of the invention to those skilled in the art. Therefore, in the specification set forth above there have been disclosed typical preferred embodiments of the invention, and although specific terms are employed, the terms are used in a descriptive sense only and not for purposes of limitation. The invention has been described in some detail, but it will be apparent that various modifications and changes can be made within the spirit and scope of the invention as described in the foregoing specification and the appended claims.

Claims (21)

1-17. (canceled)
18. An antimicrobial composition comprising benzalkonium chloride in an amount of 0.1-2.0% w/w, antimicrobial phospholipid in an amount of 0.1-1.0% w/w, and water in an amount of at least 60% w/w, wherein the composition is alcohol-free and wherein the composition is formulated for use as a skin sanitizer.
19. The antimicrobial composition according to claim 18, comprising benzalkonium chloride in an amount of 0.13%.
20. The antimicrobial composition according to claim 18, further comprising polyol co-solvent in an amount of 0.5-8.0% w/w.
21. The antimicrobial composition according to claim 20, wherein the polyol co-solvent comprises propylene glycol.
22. The antimicrobial composition according to claim 20, wherein the polyol co-solvent comprises a polyethylene glycol.
23. The antimicrobial composition according to claim 18, further comprising surfactant in an amount of 0.05-20% w/w.
24. An antimicrobial composition comprising benzalkonium chloride in an amount of 0.1-2.0% w/w, antimicrobial phospholipid in an amount of 0.1-1.0% w/w, polyol co-solvent in an amount of 0.5-8.0% w/w, surfactant in an amount of 0.05-20% w/w, and water in an amount of at least 60% w/w, wherein the composition is alcohol-free and wherein the composition is formulated for use as a skin sanitizer.
25. The antimicrobial composition according to claim 24, comprising benzalkonium chloride in an amount of 0.13%.
26. The antimicrobial composition according to claim 24, further comprising polyol co-solvent in an amount of 0.5-8.0% w/w.
27. The antimicrobial composition according to claim 26, wherein the polyol co-solvent comprises propylene glycol.
28. The antimicrobial composition according to claim 26, wherein the polyol co-solvent comprises a polyethylene glycol.
29. The antimicrobial composition according to claim 24, further comprising surfactant in an amount of 0.05-20% w/w.
30. An antimicrobial composition comprising quaternary ammonium salt in an amount of 0.1-2.0% w/w, polyol co-solvent in an amount of 0.5-8.0% w/w, and water in an amount of at least 60% w/w, wherein the quaternary ammonium salt comprises benzalkonium chloride and a second active agent selected from the group consisting of monoalkyltrimethyl ammonium salts, dialkyldimethyl ammonium salts, heteroaromatic ammonium salts, polysubstituted quaternary ammonium salts, bis-quaternary ammonium salts, and polymeric quaternary ammonium salts, wherein the composition is alcohol-free, and wherein the composition is formulated for use as a skin sanitizer.
31. The antimicrobial composition according to claim 30, comprising benzalkonium chloride in an amount of 0.13%.
32. The antimicrobial composition according to claim 30, further comprising surfactant in an amount of 0.05-20% w/w.
33. The antimicrobial composition according to claim 32, wherein the surfactant comprises cocamidopropyldimethyl betaine.
34. The antimicrobial composition according to claim 32, wherein the surfactant comprises cetyltrimethyl ammonium chloride.
35. An antimicrobial composition comprising quaternary ammonium salt in an amount of 0.1-2.0% w/w, surfactant in an amount of 0.05-20% w/w, and water in an amount of at least 60% w/w, wherein the quaternary ammonium salt comprises benzalkonium chloride and a second active agent selected from the group consisting of monoalkyltrimethyl ammonium salts, dialkyldimethyl ammonium salts, heteroaromatic ammonium salts, polysubstituted quaternary ammonium salts, bis-quaternary ammonium salts, and polymeric quaternary ammonium salts, wherein the composition is alcohol-free, and wherein the composition is formulated for use as a skin sanitizer.
36. The antimicrobial composition according to claim 35, comprising benzalkonium chloride in an amount of 0.13%.
37. The antimicrobial composition according to claim 35, further comprising polyol co-solvent in an amount of 0.5-8.0% w/w.
US15/975,482 2011-06-21 2018-05-09 Antimicrobial Composition Abandoned US20180255781A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/975,482 US20180255781A1 (en) 2011-06-21 2018-05-09 Antimicrobial Composition

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161499265P 2011-06-21 2011-06-21
US201213529470A 2012-06-21 2012-06-21
US201414211501A 2014-03-14 2014-03-14
US14/968,959 US9693564B2 (en) 2011-06-21 2015-12-15 Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate
US15/615,985 US20170265476A1 (en) 2011-06-21 2017-06-07 Antimicrobial composition
US15/975,482 US20180255781A1 (en) 2011-06-21 2018-05-09 Antimicrobial Composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/615,985 Continuation US20170265476A1 (en) 2011-06-21 2017-06-07 Antimicrobial composition

Publications (1)

Publication Number Publication Date
US20180255781A1 true US20180255781A1 (en) 2018-09-13

Family

ID=55631797

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/968,959 Active US9693564B2 (en) 2011-06-21 2015-12-15 Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate
US15/615,985 Abandoned US20170265476A1 (en) 2011-06-21 2017-06-07 Antimicrobial composition
US15/975,482 Abandoned US20180255781A1 (en) 2011-06-21 2018-05-09 Antimicrobial Composition

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US14/968,959 Active US9693564B2 (en) 2011-06-21 2015-12-15 Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate
US15/615,985 Abandoned US20170265476A1 (en) 2011-06-21 2017-06-07 Antimicrobial composition

Country Status (1)

Country Link
US (3) US9693564B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220264886A1 (en) * 2021-02-19 2022-08-25 Zoono Group Ltd Kill and Protect Surface Disinfectant and Hand Sanitizer for Combatting Contact Infection Spread
EP4057813A4 (en) * 2019-11-15 2024-01-03 New Life Crop Sciences Llc Compositions and methods for treating huanglongbing disease in citrus

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9693564B2 (en) * 2011-06-21 2017-07-04 Safehands Solutions, LLC Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate
US10975333B2 (en) 2015-07-14 2021-04-13 Ecolab Usa Inc. Controlled rate of foam breakage in hard surface cleaners
US10308897B2 (en) 2017-04-24 2019-06-04 Gpcp Ip Holdings Llc Alkaline sanitizing soap preparations containing quaternary ammonium chloride agents
CA3207112A1 (en) * 2021-01-04 2022-07-07 Harcros Chemicals, Inc. Antimicrobial compounds based on glucoheptonic acids and their salts
BR112022014619A2 (en) 2021-07-28 2024-01-23 Grignard Pure Llc PATHOGEN INACTIVATION METHODS
WO2023049119A1 (en) * 2021-09-21 2023-03-30 Laboratory Skin Care, Inc. Topical nourishing/antimicrobial compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087400A (en) * 1997-11-18 2000-07-11 Woodward Laboratories, Inc. Surfactant-based antimicrobial compositions and methods for using same
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
US20060008538A1 (en) * 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
WO2010127231A2 (en) * 2009-05-01 2010-11-04 Signal Investment And Management Co. Moisturizing antimicrobial composition

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2577773A (en) 1947-03-26 1951-12-11 Gen Aniline & Film Corp Ternary detergent compositions
US3419006A (en) 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
US3968246A (en) 1975-02-12 1976-07-06 Millmaster Onyx Corporation Disinfecting with N-trimethylbenzyl ethylenediamine
US4203872A (en) 1975-08-01 1980-05-20 Flanagan John J Surfactant system
US4278664A (en) 1976-08-12 1981-07-14 Cleave Jon S Van Preventative treatment for Otitis externae
US4321277A (en) 1978-12-04 1982-03-23 Research Lab Products, Inc. Germicidal use of compositions containing certain quaternary ammonium compounds
US4336151A (en) 1981-07-06 1982-06-22 American Cyanamid Company Disinfectant/cleanser compositions exhibiting reduced eye irritancy potential
US4657758A (en) 1984-01-27 1987-04-14 Oral Research Laboratories, Inc. Dental rinse
US4797420A (en) 1984-08-14 1989-01-10 Jabco Manufacturing, Inc. Disinfectant formulation and method of use
DE3520098A1 (en) 1985-06-05 1986-12-11 Bayer Ag, 5090 Leverkusen FORMULAS CONTAINING AZOLE DERIVATIVES AND THEIR USE FOR ATRAUMATIC NAIL REMOVAL
US5181914A (en) 1988-08-22 1993-01-26 Zook Gerald P Medicating device for nails and adjacent tissue
WO1993000100A2 (en) 1991-06-24 1993-01-07 Carrington Laboratories, Inc. Wound cleanser
AU3136593A (en) 1991-11-22 1993-06-15 Richardson-Vicks Inc. Combined personal cleansing and moisturizing compositions
DE4212105A1 (en) 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nail polish for the treatment of onychomycoses
US5362422A (en) 1993-05-03 1994-11-08 The Procter & Gamble Company Liquid hard surface detergent compositions containing amphoteric detergent surfactant and specific anionic surfactant
US5661170A (en) 1994-03-21 1997-08-26 Woodward Laboratories, Inc. Antimicrobial compositions and methods for using the same
US5550163A (en) 1994-08-03 1996-08-27 Allergan, Inc. Method for reducing filtrate waste in a manufacturing process of a pharmaceutical product containing benzalkonium chloride
US6503952B2 (en) 1995-11-13 2003-01-07 The Trustees Of Columbia University In The City Of New York Triple antimicrobial composition
JPH09301858A (en) 1996-05-13 1997-11-25 Senju Pharmaceut Co Ltd Aqueous medicine containing stabilized cholorohexidine gluconate
US5968986A (en) 1997-12-18 1999-10-19 Woodward Laboratories, Inc. Antimicrobial nail coating composition
US6022551A (en) * 1998-01-20 2000-02-08 Ethicon, Inc. Antimicrobial composition
FR2792935B1 (en) 1999-04-27 2001-07-27 Roquette Freres PROCESS FOR THE PREPARATION OF A MIXTURE OF MANNITOL AND SORBITOL BY CONTINUOUS HYDROGENATION OF GLUCOSONE
US6479039B1 (en) 1999-07-13 2002-11-12 Woodward Laboratories, Inc. Antimicrobial artificial nail composition and methods for preparing and using same
US20050192547A1 (en) 2002-01-31 2005-09-01 Modak Shanta M. Combinations of antiseptic and antibiotic agents containing medical devices
US7435429B2 (en) 2002-02-07 2008-10-14 Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
US8193244B1 (en) 2008-05-29 2012-06-05 Nevada Naturals, Inc. Antimicrobial agents
US7803746B2 (en) 2004-12-16 2010-09-28 Georgia-Pacific Consumer Products Lp Antimicrobial foam hand soap comprising inulin or an inulin surfactant
US20070048345A1 (en) * 2005-08-31 2007-03-01 Kimberly-Clark Worldwide, Inc. Antimicrobial composition
US8124061B2 (en) * 2007-11-02 2012-02-28 Kimberly-Clark Worldwide, Inc. Cleansing compositions including modified sorbitan siloxanes and use thereof
WO2011025924A2 (en) 2009-08-28 2011-03-03 Riceco, Llc Synergistic composition and method of use
US9693564B2 (en) * 2011-06-21 2017-07-04 Safehands Solutions, LLC Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087400A (en) * 1997-11-18 2000-07-11 Woodward Laboratories, Inc. Surfactant-based antimicrobial compositions and methods for using same
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
US20060008538A1 (en) * 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
WO2010127231A2 (en) * 2009-05-01 2010-11-04 Signal Investment And Management Co. Moisturizing antimicrobial composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4057813A4 (en) * 2019-11-15 2024-01-03 New Life Crop Sciences Llc Compositions and methods for treating huanglongbing disease in citrus
US20220264886A1 (en) * 2021-02-19 2022-08-25 Zoono Group Ltd Kill and Protect Surface Disinfectant and Hand Sanitizer for Combatting Contact Infection Spread

Also Published As

Publication number Publication date
US9693564B2 (en) 2017-07-04
US20160095318A1 (en) 2016-04-07
US20170265476A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
US9693564B2 (en) Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate
EP1032263B1 (en) Surfactant-based antimicrobial compositions and methods for using same
AU2012347739B2 (en) Biocidal compositions and methods of using the same
JP3777499B2 (en) Antifungal composition
ES2923403T3 (en) Medical use of a liquid antimicrobial composition
JP5986277B2 (en) Oral care method and kit
JP2007536233A (en) Treatment with polycationic antibacterial drugs
JP7470449B2 (en) Bisphosphosin gel preparations and their uses
EP2348832B1 (en) Preservative system for emulsion-based therapeutic topical formulations
US20080057136A1 (en) Disinfecting Composition and Methods of Making and Using Same
US20240008486A1 (en) Preservation of personal care compositions
US8383164B2 (en) Antiviral composition and method for using the same
JP2011074082A (en) Antiseptic sterilizer and composition for application to human body
US20100292333A1 (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails
JP2011093835A (en) Skin care preparation
JP5210527B2 (en) Antiseptic sterilizing moisturizer and composition for external application on skin and hair
EP1634589B9 (en) Aqueous olanexidine solution, method of preparing the same, and disinfectant
WO2004105492A1 (en) Aqueous compositions for disinfection and/or sterilization
JP4541661B2 (en) Disinfecting and / or disinfecting composition
EP3982735A1 (en) Compositions, kits, methods and uses for preventing microbial growth
JP2014074071A (en) Pharmaceutical composition having relatively low ionic strength
RU2292919C1 (en) Agent for skin integument disinfection
JP2022527332A (en) Antibacterial composition
JP2009167139A (en) External use composition
AU2003203452A8 (en) Topical composition

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION